See everyone. John Block with Stifel, day two of the healthcare conference. Welcome. I am happy to introduce the team from Beta Bionics, Stephen Feider, CFO, and Blake Beber, Manager of Investor Relations and Corporate Development. Guys, thanks for coming and joining us.
Wonderful to be here. Thanks, John.
We are going to hit on a bunch of different topics. You have a Mint box, and we will certainly talk about Mint for a little bit. I want to start with the 3Q26 recap. It was certainly a pretty good quarter, and new customer starts were in line. I think maybe there was some noise on 3D Intelligence, gross margin a little bit. Stock has been a bit weak since the quarter, so I am just going to toss it over to you, Stephen, just your thoughts on what might be weighing on the stock a little bit. What has the investor feedback been since the quarter?
Well, 3D was the first public promise in terms of a timeline that we have missed. When we received Mint clearance at the same press release, we included this, really the introduction of 3D as a concept, and said that it would be commercializing by the end of 2026. Since then, subsequent to that, just prior to our Q3 earnings call, FDA told us to withdraw the submission, and we have had to resubmit it. We, in fact, since then have resubmitted it, which is good news, and I can get to that.
Okay.
But that particular timeline, then we moved to mid-2027 for the 3D launch, with the potential that we could still launch it in Q4 2026. What I think some investors have been asking us about is, okay, why did that happen? Again, as a new management team to operating a public company in the eyes of some investors, I think people maybe saw that as, "Do these guys understand what's going on with their dealings with FDA?" I will comment on that in a moment, but I think that has been some of the negative sentiment we have seen. In terms of what actually happened with 3D and why did we have to withdraw the application, not to get into any particular drama here, but really, there has been no questions from the FDA on the algorithms themselves that have us at all concerned.
We do not believe that the FDA is looking at the algorithm experiences that we are launching with 3D and sees any problem with them whatsoever. Where their questions have been and what we were unable to answer within the time parameter was on validation of the simulator. I will just say briefly on what we are talking about here with the simulator is, the FDA has been more open towards insulin dosing algorithm companies or insulin pump manufacturers creating enhancements or modifications to existing commercial algorithms using simulation, which is actually great for the industry. Predicated on that is that the FDA has to agree that whatever simulation tool you have built has been validated to represent a population of people who are living with diabetes.
In the case of Beta Bionics, we were fairly certain going through that process that FDA felt good about the simulation tool and validation of it. What happened late in the submission process was we got additional feedback on our simulator and the validation associated with it that we were unable to answer within the 90-day parameter, and they asked us to withdraw it. It was disappointing for us, but that is actually what happened. I believe we have now addressed their questions, and hopefully they will pick up right where they left off. If they do not, they certainly have statutorily the 90 days to re-look at it.
Okay. I think on the earnings call, you said you are going to submit by the middle of the quarter. Just to be clear, you have already resubmitted?
Yes. We have already resubmitted.
Okay. Just to go back to what you previously said, I think to give the management team, you guys credit, you said Mint by the end of 2027, then you pull it forward to 2Q, then you pull it forward to 1Q. You said you would find a way for Type 2 adult label in sort of an efficient manner, and eventually you got there. Your point is with 3D Intelligence, it was maybe the first stumble with the agency, and people are a little bit focused on that in the near term.
Yeah. Not only that, it was our first time we have ever missed a date.
Yep
that we have communicated publicly.
Okay. Okay. How about gross margin? In the quarter was below your expectations, but you said it was really a mix thing, right? Maybe just talk to us about what was de-stocked, which I think was the pumps, which was stocked, which I think was the supplies, and if there is like a normalized GM number that you might be able to give us for 3Q.
Mm-hmm. Yeah, this area, I haven't really gotten a ton of feedback from investors subsequent to the call because I think the communication was really clear as to exactly what happened, and it can be corroborated by the numbers that we share within our disclosure documents. Just reiterating briefly, you can review our transcript if you would like. We sold fewer iLet DME pumps in the third quarter relative to the second quarter, and we sold so few that I could even clarify it with this metric. Our DME suppliers purchased fewer DME pumps from Beta Bionics than what they sold to patients in the quarter, so there was a change in the inventory balance that was pretty significant from our DME distributors on iLet in DME, which is a very high margin revenue channel for us.
On the inverse of that, the exact opposite happened with DME supplies, and those are low gross margin. That is a low gross margin revenue stream. The two of those together created an unfavorable revenue mix for the sake of gross margin. Why I do not think this is considered a problem for the sake of investors is that we did not change our guidance, and our guidance in Q4, or our calendar year 2026 guidance implies a gross margin range of 58.5%-62.5%.
Yep
in the fourth quarter. Answering your last point there, John, if you were to normalize, which I do not really like normalizing unless things are considered one time in nature, but I—
I was going to get to that.
—I understand your question, so I will attempt to answer it. I think if you were to normalize the revenue mix to be something that was more normal, let us call it, in Q3, what I believe we would have saw in terms of gross margin in Q3 is more like 59%, which is a 2% bump from where we were.
Okay.
Yeah.
That implied 4Q, I have the same numbers, 58.3%-62.7%. Lower end, mid-range? I mean, anything in particular you would point us to? Just because the implied for 4Q is obviously pretty wide with one quarter to go.
Yeah. I generally am always implying the midpoint.
Okay
when for ranges like that.
Okay. So even though it shows a pretty big step up, you are comfortable with that Q-over-Q?
Okay. 3D Intelligence, we are starting to do some work on that, and I think the early feedback from docs is it can really mean something for you guys as we go into 2027. How do we think about 3D Intelligence of the outcome? Do you expect it to have a bigger impact on, it is going to enable us to get a greater percent of share of new customer starts at a practice where we already have, where we already exist, already scripting iLet? Or is it something that can help new stores because there might have been a doc that was a little bit hesitant, for their perception of, "I want a more conservative option." Therefore, is it bringing new stores on board, or is it gaining a greater share of the existing stores?
I believe the and I will get to why in a moment, but I believe the biggest impact will be from accounts who wrote or prescribed iLet to a given subset of their patients, tried it, had a particular patient who may have had a negative experience because they experienced some hypoglycemia for reasons I could get into. But again, we do not think our clinical data on iLet creates. We think it is actually superior in terms of hypo data relative to the other competitive pumps and significantly superior relative to MDI. But in this particular case, a doctor prescribes iLet, this patient has a hypo, there is nothing for the doctor to do to change the device, and then as a result, they have lost trust in the device and they stop writing iLet. So, returning on that particular account.
Now, I do not know if you would call that a new store sale because they have actually
Right
prescribed it in the past, but that is who I think 3D will have the largest impact on. You have probably, for any investor listening here or listening to this recording, when you do endo calls, I think you probably hear that exact feedback occasionally that I just shared, is endos, and in particular, on balance, I think see the benefits of automation, which is what our value prop or our differentiation is with our product, is that it is a turn it on, set it, forget it system that determines every single dose of insulin. I actually think doctors like that. But what they have not all loved is that there is absolutely nothing they can do to change, to modify the system whatsoever. What 3D does is it adds that lever. Think of it as if everyone is driving in full self-driving in just one particular normal mode.
Some patients may prefer a Mad Max mode, some may prefer a sloth mode. But with giving them that lever is enough power or enough control to satisfy that patient or that healthcare provider's desire. But they do not actually What they are not saying when they say they want control is that they want to go under the hood into the controls and toggle individual settings and how the algorithm is learning and adapting. That is not what they are saying. They just want some control. That is what 3D does. You can probably hear it in my voice, I know for sure that 3D is underappreciated or it is underrated in terms of the investor community. I do not blame you all for that. We have not released any data whatsoever to show you what this is. All it is us, me telling theoretically.
But what we are going to see this have a massive impact. It is the number two sales objection that we get commercially for our current product. Number one is tubeless, and number two is this.
Stephen, any way to frame what I will describe as a dormant account? I will go with that, right? Like, they were writing scripts for iLet, they had something that made them pull back a little bit, and now you will have this conservative mode. Is there any way to frame, hey, 5% of our accounts went dormant, 10? Anything around there?
There is, but I do not really want to share the metric.
Okay. We will just see timing-wise when you guys get across the goal line on 3D.
That is right.
Okay.
Been submitted. We have hopes that it could still come this year, but more likely first half 2027.
Okay.
If I may as well, this draws back to your first question around just reaction and general takeaways and questions we are getting from earnings. I think one thing that may have been unclear on the call that we have gotten questions on is whether the potential delay of 3D Intelligence impacts our Mint launch timing and what it looks like as far as rolling out 3D goes. To clarify that piece, it does not impact our timing for full Mint launch in Q1. We are able to launch Mint without 3D. As Mint, we do not expect that to impact Mint, especially in the early days. As far as rolling out 3D goes, it is just a firmware over-the-air update to anyone on a Beta Bionics product, whether that is an iLet or Mint, you could do that overnight.
If we happen to get the 3D clearance prior to the Mint launch, we will ship out the reusable component of Mint with 3D already on it.
Okay. Got it. So easy, even if the Mints start going out the door, you get 3D Intelligence 3 months later, you just push it out overnight and everyone has that capability.
You got it.
Okay. Fair enough. That is probably a good segue to Mint. I will start with manufacturing in 2027. You talked about 1.5 million units for the year, gets you to roughly 20,000 customers for 2027?
No, actually more than that. The reason that your math may be a little wrong is, we will launch with significantly less annualized capacity than 1.5 million.
By the end of 2027, we will have an annualized manufacturing capacity of far greater than 1.5 million.
I'm getting like 2.5 million. Is that
Directionally, that's fine, yeah. But that would end up at 135 Mints per year, and again, growing that manufacturing capacity, we will have slightly more new starts on Mint, I believe, in 2027 than that number.
Okay. That's helpful, so I'll jump around. The more than 20,000, we'll go with 2/3, 1/3 is the thought in terms of what's going to be earmarked ideally for new customer starts versus iLet to Mint upgrades.
Well, yeah. I think that over the fullness of time, somewhere between 80%-90% of all Beta Bionics users are going to prefer Mint, or that they do prefer Mint, I should say. So that 1/3, just restating what John Block said a moment ago, he's saying of all the new starts that we have on Mint in 2027, 2/3 of them are new to Beta Bionics and 1/3 are iLet going to Mint. That 1/3 number could be a lot higher if we had enough manufacturing capacity to satisfy it. So it's us allowing a certain portion of our existing iLet users to transition to Mint while prioritizing new users on the product.
Here in all this, that what I'm extremely confident in at the moment, based on initial demand, experience from people who are already using Mint, endocrinologist feedback from what they know about the product, that we will sell what we make in 2027 in terms of Mints. This point that you brought up, and I think we must have shared on a prior call with you, this 2/3, 1/3, it's more of an allocation discussion for how we plan to operate the business, not like the limitations of demand.
How do you control that dynamic? Let's just say there was a lot more that wanted Mint out of the gate in your current install base. How do you put some parameters around, I don't want to say want more than 1/3, but obviously you'd rather have the new customer starts, just from sort of a P&L perspective. What are the sales force marching orders or how you control that dynamic a bit?
Mm-hmm. It may not be immediately obvious, but there's one key detail about our operational model when we launch Mint that actually allows us to do this, and it's that we operate our own pharmacy. Every single Mint will get prescribed to Beta Bionics pharmacy, and then we actually then have the patient demand captive at our pharmacy, where then we can dictate what demand gets fulfilled and we can interact with the patient to characterize where they are in terms of their process or their timeline in order to get the product. I think that addresses your question, if you kind of see what I mean by this. Where this would be really challenging is, let's say Mint was only available in retail pharmacies. We would have no idea where the demand was.
If you got prescribed a Mint, and you wanted it to be sent to Costco, I don't know if you're a Costco guy, I am, but you'd get it sent to Costco, we wouldn't be privy to that prescription. We wouldn't know it existed, until you started on Mint and synced it to your phone. In our case, because all the prescriptions get sent to Beta Bionics, we can then have the ability to control demand, and we've created our own algorithm, per se, for how we plan to do that.
Okay.
Now, I'm not suggesting this is going to be perfectly quiet and elegant. People who want Mint who are on iLet, we would love to be able to provide that to them, and I think there will be hard conversations. I'm not suggesting, "Oh, yeah, John, this is going to be super easy and the patients won't mind.
He gets it.
Everyone understands there's scarcity for new products. That's not really the world we live in today. People expect when they order something, it shows up the next day.
Okay. That was helpful color, though. That was good context. Maybe just a couple more down this road. I think we all have our own models and new customer start assumptions. We had you guys running around high single-digit share of new customer starts with iLet, maybe for most of the past handful of quarters. When we take a step back, Mint, huge introduction, big priority for the company, gets you into that patch pump market. How do we sort of translate that and walk it back to your percent of new customer starts for 2027?
Well, embedded in the revenue consensus numbers is a growth in new patient starts that is pretty significant. It goes up from what you are saying is high single digits, so it will grow in terms of percentage of new patient starts, but I do not want to be specific about the exact percentage. That is the direct answer. I think it is important that I just say, we have built Mint and we are building this company to be the market leader.
It is entirely uninteresting to me and Sean, our CEO, to build a company that is targeting a narrow portion of the market. We are coming for the market-leading product here, and the internal planning is to, as quickly as possible, become the leader of all insulin pumping. I think that will happen over a period of time that I do not want to quantify because I do not like long-range guidance. Do not think of us as like, "Oh, yeah, this whatever mid-single digit growth.
We want to go to 11%.
Yeah, we are trying to go to 11%, and then maybe the next year we will go up another couple. That is not the vision. The vision is scale manufacturing for Mint as fast as possible to get it to the level where our incumbent is, or the patch pump incumbent, and crush the competition.
Okay. Guys, if you have any questions, please throw your hand up. A handful more on Mint. We're all, I'll speak for myself, maybe somewhat obsessed on this. At 1.5 million, and is your exit rate 2.5 million in capacity, what other variables or dynamics could constrain the launch or Mint starts, whether it's around customer support, maybe talk about reimbursement, where it starts, where it goes, just away from purely the manufacturing side of things?
Well, there are so many potential constraints. Yes, you could say reimbursement is one of them, but I'm not worried about that one. We will launch with at least 40% of all patients who can buy Mint using their pharmacy benefit, growing to 50% by the first year. Mint, you could make a case supply chain, but I feel good about the components that we are using within Mint and our order volumes and the orders that we already have in place and the reliability of those suppliers, second sourcing of single-source suppliers. I feel good about that. Those are just two examples. You could also say, yeah, the commercial infrastructure and the plumbing associated with operating the company. That's what you're buying, right?
To me, that's a big benefit of launching a product like Mint to an existing company who already has over $100 million in revenue and a fully functioning commercial infrastructure. The systems are very much in place for the company to be 10x the size, and it would scale certainly marginally, but you get the point. To me, the real constraint on our ability to manufacture Mint just comes down to the actual nuts and bolts on the manufacturing line. These Mints today, I'm holding a, I'm trying to call it a box, but yeah, it's a starter kit that contains 10 Mints in it. These are being made in our Irvine facility on the manufacturing line that we're operating with several shifts. But today, it's mostly done by humans. It's in its crawling stage. We have humans moving the pieces from one station to the next.
There's about 20 stations. Frankly, for a variety of reasons, we can't get to building 10 million a year if we don't change the manufacturing lines, the design system. Meaning, if we were to just say, "Oh, yeah, what we're going to do is just duplicate that manual line and put it in for the rest of the facility or expand that Irvine facility," there's too many things that would break. That's way too many people. The turnover would be insane. What is happening in parallel to our crawling stage to get to the walking stage is we are adding robots or automation to move the material handling from one station to the next, removing some of the humans from the process and making the processes more reliable.
That is already in motion. If you are going to bet on our ability to exceed the 1.5 million of capacity in 2027, which, to be clear, we are calling that a minimum number of Mints that we manufacture, you are betting on our ability to add automation to that process.
Okay
in the short term. Now, another question I get occasionally from people who I realize you guys cover tons of names, is that this is a 510(k) product, Mint, and there is no line validation required regulatorily in order to make changes to the manufacturing line. We do not have to submit a bunch of documents to the FDA when we want to add these robotics. As long as it fits within our quality standards and the specs of the product do not change, we can make these changes to the actual manufacturing environment without any regulatory submission.
Hence doing it in parallel.
Hence doing it in parallel, and also that just makes any changes that you would make to that extremely quick, relative to a process like a PMA where you had to submit the manufacturing.
Okay.
Yeah.
That is another good segue when we are talking about automation to the gross margin side of things. You talked about this being diluted to corporate gross margins in 2027. I think the Street is sort of low 50s gross margin. That is near term. You have talked long term about this being at a margin or maybe even superior to that of the market leader. How about sort of the midterm? When does Mint's gross margin profile cross over current corporate or iLet? Is that a 2028 phenomenon?
Yeah, I do not like giving more guidance, like longer range, but I will give you a framework you can use to directly answer your question. John is getting at is that today we are high 50s gross margin as a company. Next year, we will drop to low 50s while embedded in if the iLet gross margin profile does not change in 2027, iLet being what we currently sell, then that means that Mint's overall gross margin is somewhere in the 40s, okay? What I have also said, and I will just reiterate, is that within three years of launching Mint, we believe that Mint will have a gross margin profile that is as good or better than the current patch pump incumbent. There are reasons for that. The design decisions of our product allow that to be true.
Between those two periods, what I expect to see is that you will see continued improvement in gross margin, where the line, I think, will be relatively linear. I do not want to be held to that necessarily. You can look for my guidance in each of the respective quarters and years, but directionally, there is no massive step change. You are not going to see us come along at a 40% gross margin, then just a massive step change to something above 70. It will be more gradual.
That sort of implies just the layering in of the automation along the way and the scale along the way.
That's right. The main ways this. The bill of materials on Mint is already actually pretty low, so the material costs associated with it, frankly, because there's just not much in each of the Mints. There can only be so much compression on that. The materiality on improvements there is reasonably low. The opportunities come from removing direct labor from the product, which I just communicated is even a near-term problem that we'll solve. The fixed manufacturing overhead is really a scale problem. You have a fixed manufacturing overhead cost structure, and the more Mints that you make, the more units that spread over, and that's the easiest way, or that is the easiest lever within your cost per unit to grow or to improve as you scale.
Okay. A couple more on Mint, then maybe we'll hit on a few other topics to close. Just, if you had to call out the two or three variables that allows Mint to win, and we're going to actually have a doc panel here at lunch on diabetes and have two leading endocrinologists, but it's not just an Omnipod thing, right? Because the competitive environment isn't going to be static. You're going to have Mobi, you're going to have Fit. Just for the audience, what would you emphasize the two or three characteristics that allow it to win against the other handful of players that will be out in the market in 2027?
Mm-hmm. I'll be fast here, and you can ask any follow-ups because we could talk really long about it. But against the current incumbent patch pump, it's our algorithm. That's the winning. The form factor is as good or better, and the user experience, in our belief, is as good or better from the actual design of the form factor, but the algorithm is a massive improvement. So relative to that particular competitor, that's how we'll win. Relative to the other ones coming, two reasons. One is size profile. Size really does matter, and the size of our product and the incumbent are smaller in terms of both weight and the dimensions of the product than the other two that are coming. So I think that's one. The second is recharging of the device.
So with the current patch pump that's on the market, it's fully disposable, no recharging required. Our belief structure was that that is a nice characteristic of the product, and any patch pump has to have that same characteristic to it in order to be competitive. So we've designed Mint where the batteries are in the disposable, which you throw away every three days, and that powers on to the control. When you connect the controller and the disposable together, it powers on the devices, and there's no recharging associated with it. So the device I'm holding in my hand here, which is the controller part of Mint, that's where all the intelligence lives. This is what lasts two years. Patients get one of these. There's no charger for this. Again, there's no batteries in it. It only works when it's plugged into a Mint.
Okay. Any follow-up questions on that, on what allows them to win? Let's see what we can get through in three minutes. You mentioned earlier, Stephen, that maybe 80% or 90% of iLet people would want a Mint. Formulary coverage starts at 40% for Mint out the gate, 50% by year-end 2027. Can you approach 70% or 80% by the following year, where essentially you're further along in terms of removing that as a barrier?
Sorry, I don't want to answer that one. I don't want to give guidance beyond that. I do have confidence in our ability to get to By the way, I don't know if it's ironic that you shared that percentage, but directionally, that's where I think our patch pump competitors' reimbursement is today.
The 70%, 80%?
Yeah. I think it's actually quite a bit easier for the second comer to the market to get to that kind of level than what it's taken them. They paved that road for patch pumps and reimbursement, but I don't want to give you an exact timeline of when I think that'll be.
Okay. Last few topics. Sales reps. In the background, you have done a good job of increasing the sales force ahead of Mint, ahead of 3D Intelligence. Maybe talk about the retention of that sales force, and you are still smaller than, call it, your bigger competitors. What else, if anything, do you need to do from a sales rep perspective in 2027?
Well, I like the size of our sales force today in anticipation of the Mint launch. We may grow the sales force marginally in 2027, but you are not going to see a massive uptick.
Okay.
Retention, we have been retaining the sales force at a level that it meets my expectations. That particular function of the business has a turnover rate that is consistent with everywhere else in the company. I think you actually want some turnover. This may sound a little draconian, but your lowest performing territories, you actually want out. That is just the nature of the game. If I was a company sitting up here and saying, "We have retained every sales rep in the last two years," that to me means you have too rich of an incentive comp plan or—
You are keeping your bottom performers.
—or you're keeping your bottom performers, yeah.
Yeah.
So.
Yeah. I'll just hit on maybe some 2027 thoughts, which you've already conveyed at a high level. I think you said you're comfortable with where the Street is in 2027 because some of that deferred revenue comes out of 4Q 2026 into 2027. We discussed low 50s GM. OpEx as a percent of sales delevered this year in 2026, even with good top line growth because of hiring the reps. I don't think cash is a problem because you just did a very big successful raise, but do we see OpEx leverage come into the fold in 2027 as maybe some of the incremental reps step down?
Yeah. That was really well characterized, by the way. But yes, we do, and we'll see that at every line item within OpEx.
Okay. Last one, 10 seconds, fully closed loop. You said that will be initiated this quarter on Type 1 and Type 2. Anything high level around timing for approval?
Don't want to share approval timelines at this time, but I think what you'll see from the posting on clinicaltrials.gov, generally speaking, 13-week primary efficacy HbA1c outcome, roughly 400 patients enrolled. I think the timelines, or at least the study, will generally look like what you're used to traditionally in this space. I think the timelines can generally be anchored to maybe what you're previously used to.
Okay. Thank you. I didn't want to end on, "I can't answer that question," so that was very helpful. Thanks, guys. Appreciate it.
All right. Thank you.